

Index

Page numbers followed by italicized *b*, *f*, and *t* indicate boxes, figures, and tables, respectively.

A

Access

barriers to

for elderly, 263, 265

insurance and, 12–13, 268

children and, 253

elderly and, 265

as reason for nonutilization, 84*t*–86*t*

removal of, 4, 12–13, 19, 268, 286

and dental care utilization, among military vs. civilian population, 83, 87, 88*f*

ACF. *See* Administration for Children and Families

Acids

and caries, 37–38

saliva and, 27

and tooth surfaces, 31

Actinobacillus actinomycetemcomitans

and adult periodontitis, 40

and bacteremia, 104

and early-onset periodontitis, 42, 205

and periodontal disease, 203*t*

Administration for Children and Families (ACF), 226, 226*t*

Adolescents/young adults, 257–258. *See also* Children

Adult periodontitis, 40–42

bacterial activity in, 40, 203*t*, 204–205

diagnosis of, 204–205, 204*t*

immune response to, 40–41

progression of, 40

rapidly progressing, 40, 41, 207

refractory, 42

susceptibility factors, 41

systemic antibiotics for, 207

Adult respiratory distress syndrome (ARDS), 105

African Americans. *See also* Race/ethnicity
cancer in

incidence of, 68, 68*f*

survival rates for, 68–69, 69*f*

children, insurance coverage of, 253, 278

congenital malformations in, 72, 72*f*

dental care among

nonutilization of, 83, 84*t*

utilization of, 80*t*, 81–82, 81*t*

dental caries in, 63–64, 63*f*, 64*f*

as dental personnel, 236–237, 237*t*

oral and pharyngeal cancers in

diagnosis of, 69, 69*f*

by sex, 68, 68*f*

oral health status of, 74–75

periodontal disease in, 65–66, 66*f*

and ratings of oral health, 144

tobacco use by, 260*b*

tooth loss in, by economic status, 67, 67*f*

toothaches among, prevalence of, 73

Age

and canker sores, prevalence of, 71, 71*f*

and dental care

nonutilization, 83, 84*t*

utilization, 80–81, 80*t*

and dental caries, by economic status and race/ethnicity, 63–64

and injuries, 72–73

and insurance coverage, 231

and oral-facial pain, prevalence of, 73, 73*f*

oral health data on, 2–3

oral health vulnerabilities according to, 249–267

and oral herpes lesions, prevalence of, 70–71, 71*f*

and periodontal disease, 65–66, 65*f*, 203*t*

adult periodontitis, 41

by race/ethnicity, sex, and economic status, 65–66

- Age (*continued*)
 and ratings of oral health, 144
 and tooth loss, 66
- Agency for Healthcare Research and Quality (AHRQ), 171, 172, 213, 225, 226t
- Aging, and craniofacial complex, 31–32
- AHRQ. *See* Agency for Healthcare Research and Quality
- AIDS. *See also* HIV infection
Candida infections with, 43
 esophageal candidiasis with, 101
 and oral cancer, 46
- Alcohol, 191t
 community programs, 171
 as general health risk factor, 10
 in mouthwash, and oral cancer, 210
 and oral cancer, 44–45, 46, 169, 208t, 209, 209t
 tobacco and, combination of, and oral cancer, 45, 208t, 209
- Allodynia, 52
- Allografts, 208–209
- Alloplasts, 209
- Allopurinol mouthwash, and mucositis, 106
- Alpha tocopherol, 47, 251b
- Alveolar bone. *See also* Jaw; Oral bone
 aging and, 31–32
 loss of, 32
 osteoporosis and, 102–103
 risk factors for, 203t
 smoking and, 41
 nutrition and, 250b
 regeneration of, 208–209
- Amelogenesis imperfecta, 49, 278
- American Indians/Alaska Natives
 children of, oral health of, 76–77
 as dental personnel, 236, 237t
 oral and pharyngeal cancers and, by sex, 68, 68f
 oral clefts, 72
 oral health status of, 76–77
 Pima tribe, in diabetes-periodontal disease study, 113–114
 and precancerous lesions from smokeless (spit) tobacco, 70
 and ratings of oral health, 144
- American Society of Anesthesiologists, classification of patient's risk, 196, 197t
- Americans Stop Smoking Intervention Study for Cancer Prevention (ASSIST), 171
- Anaerobes, gram-negative, 39
- Andersen behavioral model, 248–249, 248f
- Anodontia
 in ectodermal dysplasias, 50
 hereditary, 49
- Antibiotics
 and disruption of oral homeostasis, oral candidiasis and, 42
 systemic, for periodontitis, 206t, 207
- Antibodies. *See also* IgA antibody; Immunoglobulins
 in adult periodontitis, 40–41
 in mucosal immune system, 28
 oral fluids in diagnostic tests for, 103, 103t
- Anticipatory guidance, for children, 256
- Antigenic components, in identification of periodontopathic bacteria, 205
- Antimicrobial agents, for periodontal diseases, 206t, 207
- Antimicrobial components, in saliva, 27
- Antioxidants, 47
- Apert's syndrome, 49
- Aphthous ulcers, recurrent, lesions caused by, 100t
- Apoptosis
 and oral cancer, 45, 46
 Sjögren's syndrome and, 51
- ARDS. *See* Adult respiratory distress syndrome
- Arthritis, jaw manifestations of, 52
- Ascorbate, and gingivitis, 250b
- Asians/Native Hawaiians/Pacific Islanders. *See also* Chinese Americans; Vietnamese Americans
 as dental personnel, 236, 237t
 oral and pharyngeal cancers and, by sex, 68, 68f
 oral health status of, 76
- Aspartate aminotransferase, in adult periodontitis, 205
- Assaults. *See* Violence
- ASSIST. *See* American Stop Smoking Intervention Study for Cancer Prevention
- Association of State and Territorial Dental Directors (ASTDD), 226–227
- ASTDD. *See* Association of State and Territorial Dental Directors
- Autografts, 208
- Autoimmune disorders, 212
 Sjögren's syndrome, 51

B

- B cells, 28
- Bacteremia
 infective endocarditis and, 107–108
 and microthrombosis, 117–118
 and oral infection, 104–105
- Bacteria. *See also specific bacteria*
 in adult periodontitis, 40, 41, 204–205
 in dental caries, 37–38
 in early-onset periodontitis, 42, 205
 in gingivitis, 39
 gram-negative, and adult periodontitis, 40
 in heart disease, 117–118

- lesions caused by, 99t
 in periodontal disease, 202, 203t, 204–205
 in refractory periodontitis, 42
- Bacteroides forsythus*
 in adult periodontitis, 40, 205
 in periodontal disease, 203t
- BANA test, in identification of periodontopathic bacteria, 205
- Behçet's syndrome
 lesions caused by, 100t
 and RAU, 44
- Benzpyrene, 45
- Betel nuts, and oral cancer, 45
- Biofilm, 26, 37, 104. *See also* Plaque
 and gingivitis, 39
- Biomarkers
 future of, 279
 for oral cancer, 210
- Biomimetics, 279
- Biopsy
 for mucosal disease diagnosis, 212
 for oral cancer diagnosis, 210
- Birth control medication, and gingivitis, 39
- Birth defects, craniofacial, 47–50
 clinical management of, 210–211
 cultural reactions to, 141
 point mutations and, 31
 prevalence of, 71–72
 prevention and control of, 172–173, 210–211
 strategies for, 156t
 secondary to other developmental disorders, 49
- Bone grafts, 208–209
- Bone loss. *See* Alveolar bone, loss of; Oral bone, loss of
- Boston-type craniosynostosis, 49
- Brain abscesses, oral flora and, 105
- Branchial arch(es), 29
 altered morphogenesis of, birth defects caused by, 47–48
- Bruxism, 52, 190, 191t
- Burkitt's lymphoma, viral causes of, 45
-
- C**
-
- Calcium
 metabolism of, disturbances in, oral manifestations of, 101
 and periodontal disease, 203t, 250b–251b
- Calcium channel blockers, and gingivitis, 39, 107
- Calculus
 and adult periodontitis, 40
 and gingivitis, 39
- Campylobacter*, and gingivitis, 39
- Canadian Task Force on the Periodic Health Examination, 156–158
- Cancer. *See also specific type*
 oral and pharyngeal, 44–47, 209
 health care providers' knowledge about, 179
 HPV and, 43, 45–46, 208t, 209, 210
 prevention and management of, 47, 169–172
 community-based interventions, 170–171
 early diagnosis in, 171–172
 nutrition in, 210, 251b
 provider-based, 210
 strategies for, 156t
 public knowledge about, 178–179
 quality of life with, 136, 142
 risk factors in, 44–47, 208t, 209–210, 209t
 nutrition and, 251b
 statistics on
 incidence rates, 67, 68, 68f, 74
 mortality rates, by state, 70, 70t
 site-specific, 69–70
 sources for, 62
 stage of diagnosis of, by race/ethnicity, 69, 69f
 survival rates, 67–69, 74
 tobacco and, 259b, 260b
 therapies. *See also* Chemotherapy; Radiation treatment
 combined, and oral mucositis, 106–107
 types of
 incidence rates for, 68, 68f
 survival rates for, 69, 69f
- Candida albicans*
 and oral cancer, 46, 209
 and oral candidiasis, 42
- Candida* infections, 42–43
- Candidal angular cheilosis, 43
- Candidiasis
 esophageal, 101
 lesions caused by, 99t
 oral, 42–43
 with HIV, 42, 43, 71, 101
 prevalence of, 71
- Canker sores, 43–44. *See* Recurrent aphthous ulcers (RAU)
 prevalence of, 71, 71f
- Capnocytophaga*, and prepubertal periodontitis, 42
- Capnocytophaga ochracea*, and localized juvenile periodontitis, 42
- Capsaicin, 25
 for oral mucositis pain, 106
- Carbamazepine, and tic douloureux, 52

- Cardiovascular disease, oral infection and, 115–120
 animal studies, 117–118
 mechanisms of action in, 115–117
 population-based studies, 118–120, 119t
- Caries. *See* Dental caries
- Cariou lesions, precavitated, in restored teeth,
 diagnosis of, 198
- Carotenoids, 47, 251b
- Cavities, 37. *See also* Dental caries
- CDC. *See* Centers for Disease Control and
 Prevention
- Celiac disease, oral manifestations of, 101
- Cements, glass ionomer, in dental caries treatment,
 201
- Center for Policy Alternatives, 268
- Centers for Disease Control and Prevention (CDC),
 225, 226t
- Cervical cancer, human papillomavirus (HPV) and,
 43, 45
- Cervicofacial actinomycosis, lesions caused by, 99t
- Chediak-Higashi syndrome, and periodontal
 disease, 41
- Chemotherapeutic agents, in plaque reduction, 199
- Chemotherapy
 oral candidiasis and, 42
 oral infections from, 105
 oral ulcers and oral mucositis from, 26
- Chickenpox, oral lesions with, 98t
- Children
 anticipatory guidance for, 256
 craniofacial birth defects in. *See* Birth defects,
 craniofacial
 dental caries in, 2, 38, 252
 by economic status and race/ethnicity,
 63–64
 dental risk and protective factors for, 257t
 dental sealants for, 167–168, 168t
 with disabilities, 79, 253
 enamel fluorosis in, 160
 fluoride for
 in dietary supplements, 162–165, 164t
 in mouthrinses, 165
 in school water, 162
 from supplement programs, 164–165
 future of oral care and, 277–278
 injuries and, 258t, 722
 insurance coverage, 231, 253, 277–278
 Medicaid, 2, 253–255, 268
 State Children's Health Insurance Program,
 13, 233–234, 255, 277
 malocclusion in, risk and protective factors for,
 258t
 oral health of, 2, 249–253
 barriers to, 13, 286
 preventive environment for, 255–257, 256t,
 257t, 258t
 periodontal diseases in, risk and protective
 factors for, 256t
 poverty and, 2, 252
 violence and abuse, 51
- Chinese Americans, nasopharyngeal cancer
 incidence and mortality, 76
- Chlorhexidine
 to limit gingival inflammation, 205, 206t
 to prevent mutans streptococci transmission,
 200
 and remineralization, 199
 teeth stains from, 107
- Chronic and disabling oral conditions, 51–53, 73
- Cigarettes, and oral and pharyngeal cancer, 259b.
See also Tobacco
- Cigars. *See also* Tobacco
 and oral and pharyngeal cancer, 259b
 and oral cancer, 208t, 209
 trends in smoking, 260b
- Cleft lip/palate, 47–48
 cost of, 228
 prevalence of, 72, 72f
 quality of life with, 141–142
 in Waardenburg syndrome, 50
- Cleft palate, 47–48
- Clefting abnormalities
 from altered branchial arch morphogenesis,
 47–48
 incisive foramen and, 30
- Cleidocranial dysplasia, 50
- Cochrane Collaboration, 213, 214t, 246
- Collagenase, in adult periodontitis, 205
- COMMIT. *See* Community Intervention Trial for
 Smoking Cessation
- Community Health Centers, 227, 237
- Community health programs. *See also* Public health
 programs
 for craniofacial birth defects, 172–173
 for dental caries, 158–168
 evidence of effectiveness of, 155–158
 glossary of terms, 157b
 for injury, 173–176
 for oral and pharyngeal cancers, 169–172
 for periodontal diseases, 168–169
 strategies used, 156t
- Community Intervention Trial for Smoking
 Cessation (COMMIT), 171
- Corticosteroids, and disruption in oral homeostasis,
 oral candidiasis and, 42
- Cosmetic dentistry, increased demand for, 137–138
- Coxsackievirus, oral lesions with, 98t
- Cranial bones, birth defects involving, 48–49

- Craniofacial complex
 aging of, 31–32
 contact and communication in, 23–25
 diagram of, 22
 functions of, 1, 17
 oral cavity in, 25–28
 origins and development of, 28–31
 early development of, 29–30
 genetic controls in, 30–31
 nutrition in, 250*b*
 research on, 4, 19
 sensory functions of, 23
 Craniofacial defects. *See* Birth defects, craniofacial
 Craniosynostosis, 49, 278
 and gene mutations, 31
 Crohn's disease, and RAU, 44
 Crouzon's disease, 49, 278
 Cryotherapy, for mucositis, 106
 Cuban Americans, oral health of, 75
 Cyclosporin, and gingivitis, 39, 107
 Cytokines, 28
 and adult periodontitis, 40–41
 and periodontal diseases, 203
 and pregnancy, 120–121
 Cytomegalovirus, and chemotherapy, 106
- D**
-
- Demineralized bone, freeze-dried, in bone grafts,
 208–209
 Dental appliances, 201
 and chewing function, 135–136
 and oral candidiasis, 43, 71
 Dental care. *See also* Oral health care system
 active personnel in, 223–224, 224*t*, 235–236,
 235*f*
 composition of, by sex and race/ethnicity,
 236–237, 237*t*
 annual expenditures on, 223, 228, 228*t*, 231*f*,
 231*t*
 per capita, 228, 229*f*
 vs. total health care expenditures, 227,
 227*f*, 228*f*
 costs of
 indirect, 142–144, 143*t*
 per capita, 228, 229*f*
 as reason for nonutilization, 83, 84*t*–86*t*
 vs. other medical services, 228, 230*t*, 231*f*
 disciplines in, 224
 evidence-based, 213, 246, 277
 expenditures on, 227–228
 by source
 1960–1996, 231*f*
 1998, 228*t*
 vs. total health care expenditures, 227*f*,
 228*t*
 financing and reimbursement for, 228*t*,
 229–234, 231*f*, 231*t*, 232*f*
 managed, 231–233, 233*t*, 254
 among military personnel, vs. civilian
 population, 83, 87, 88*f*
 nonutilization of, reasons for, 83, 84*t*–86*t*
 population-to-dentist ratio, 224, 224*f*
 for underserved populations, 239
 unmet needs in, 83, 87*t*
 for children, 252–253
 utilization of, 80–81, 190–191
 by sex, race/ethnicity, income, and
 insurance, 80*t*, 81–82, 81*t*
 variation by oral health status, 82, 82*t*
 Dental caries, 37–39
 changing clinical approach to, 196–201
 diagnosis of, 198, 200*t*
 multifactorial model in, 196, 197*f*
 prevention of, 198–200, 200*t*
 risk assessment in, 197, 198*f*, 198*t*, 199*t*,
 200*t*
 treatment of, 201
 in children, 2, 38, 252
 by economic status and race/ethnicity,
 63–64
 risk and protective factors for, 257*t*
 classification of, 201
 nutrition and, 250*b*
 prevalence of
 by age, economic status, and race/ethnicity,
 63–65
 prevention of
 community approaches to, 158–168
 dental sealants, 166–168
 dietary fluoride supplements, 162–165
 fluoridated drinking water, 160–162
 fluoride mouthrinses, 159*t*, 165
 fluoride varnishes, 165–166
 school water fluoridation, 162
 fluoride in, 2–3, 10, 18, 27, 38, 155,
 158–160
 health care professionals' knowledge about,
 177–178
 provider-based, 198–201
 public's knowledge about, 177
 saliva and, 27, 38
 strategies for, 156*t*
 target population for, 159*t*
 daily hygiene, 39, 189–190
 progression of, 198
 rate of, 38–39
 smokeless (spit) tobacco and, 39, 259*b*

- Dental caries (*continued*)
 susceptibility to, 39
 tobacco and, 259*b*
 vaccine for, 200
- Dental hygienists, 235
 knowledge of dental caries prevention, 177–178
 knowledge of periodontal disease prevention, 178
- Dental implants, 201
- Dental plans. *See* Insurance
- Dental plaque. *See* Plaque; Biofilm
- Dental practice, 223–224
- Dental schools
 curriculum needs of, 237–238
 enrollment, 235
 of minorities, 236
 faculty vacancies, 237
 graduate indebtedness, 237–238
- Dental sealants, 38, 166–168
 for children, 167–168, 168*t*
 combined with fluoride use, 167
 cost-effectiveness of, 168
 in dental caries treatment, 201
 effectiveness of, 159*t*, 166–167
 prevalence of use, by race/ethnicity, 82
- Dentifrice, 159*t*, 176, 177, 179, 189–190
- Dentinogenesis imperfecta, 49
- Dentists
 availability of, 224
 charitable care by, 239
 compensation of
 from elderly in long-term care, 265
 from Medicaid, 254
 increased importance of, 191–192
 knowledge of dental caries prevention, 177–178
 knowledge of periodontal disease prevention, 178
 numbers of, 223–224, 224*t*, 235–236, 235*f*
 visits to. *See also* Dental care, utilization of
 and susceptibility to adult periodontitis, 41
- Denture sore mouth, 43
- Denture stomatitis, 43, 71
- Depression
 atypical facial pain with, 52
 with cancer, 142
 with TMD, 140
- Dermatologic diseases, lesions caused by, 100*t*
- Developmental disorders, 47–50
 clinical management of, 210–211
 cultural reactions to, 141
 prevalence of, 71–72
 prevention and control of, 172–173
 strategies for, 156*t*
- dfs, definition of, 62*b*
- dft, definition of, 62*b*
- Diabetes mellitus
 and adult periodontitis, 41
 and periodontal disease, 2, 17, 109–115
 research used in, 110*t*, 111*t*–113*t*
 treatment of, 206
 type 1, and periodontal disease, 41, 110–113, 114, 203*t*
 type 2, and periodontal disease, 113–114, 203*t*
- Diagnostic codes, dentistry, 216
- Diagnostics, saliva and oral fluids in, 103–104, 103*t*, 279, 280*t*
- Diet. *See also* Nutrition
 effect on oral health, 191*t*^{*}
 and oral and pharyngeal cancer, 209*t*
 poor, as general health risk factor, 4, 10, 18
- DiGeorge syndrome, 48
- Digital radiography, 196
- Dilantin, and gingivitis, 39
- Disability days, due to dental conditions, vs. other conditions, 143, 143*t*
- Disabled population, oral health of, 78–79
- DMFS, definition of, 62*b*
- DMFT, definition of, 62*b*
- DNA
 in identification of periodontopathic bacteria, 205
 saliva as source for, 103–104, 103*t*
- Down syndrome, and periodontal disease, 41
- Drug abuse, oral fluids for diagnosis of, 103, 103*t*
- Dry mouth. *See* Xerostomia
 and dental caries, 38
 and chewing function, 136
 and Sjögren's syndrome, 51, 136
- Dysplasia, 46
-
- E**
-
- Early and Periodic Screening, Diagnostic and Treatment Service (EPSDT), 254
- Early childhood dental caries (ECC), 38, 228
- Early-onset periodontitis, 42
 bacteria linked to, 205
 by sex and race/ethnicity, 66
 systemic antibiotics for, 207
- Eating problems, and quality of life, 135–136, 136*t*
- ECC. *See* Early childhood dental caries
- Ectodermal dysplasias (EDs), 49–50, 211
- Edentulism
 by age, economic status, sex and race/ethnicity, 66–67
 by economic status, 82
 and heart disease, 119
 by state, 67*t*

- and stroke, 120
- EDS. *See* Ectodermal dysplasias
- Education level
- and dental care wants, 87t
 - and dental visits, 80t, 81, 81t
 - and insurance coverage, 231, 232f
 - and knowledge of periodontal disease, 178
 - and susceptibility to adult periodontitis, 41
- Educational debt, 237–238
- Efficacy, of health programs, vs. effectiveness, 155–156
- EGF. *See* Epidermal growth factor
- Egg polarity genes, 30
- Eikenella corrodens*
- and adult periodontitis, 41
 - and prepubertal periodontitis, 42
- Elastase, in adult periodontitis, 205
- Elderly adults. *See also* Age
- chronic health problems of, 266, 266t
 - eating problems of, 135–136, 136t
 - oral health of, 3, 262–266, 263t, 264t.
 - trends in, 265–266
 - research on, 262, 263t, 264t
 - sleep problems of, 137
 - social functioning of, 138–139, 139t
 - women, 266–267
- Electrical resistance measurement, 196
- Enamel
- age and, 31
 - demineralization of, 38, 199
 - remineralization of, 199
 - fluoride and, 159
 - saliva and, 27, 31, 38
- Enamel fluorosis, 160
- Enamel hypoplasia, 101
- from tetracycline, 107
- Endocarditis, infective, oral infection and, 107–108
- Endocrine system
- and disruption in oral homeostasis, oral candidiasis and, 42
 - and immune system, 28
 - nicotine and, and oral and pharyngeal cancers, 46–47
- Environment
- importance of, 248–249, 248f
 - improvement of, 268
 - for children, 255–257, 268
- Epidemiologic data, need for. *See* Data
- Epidemiology, definition of, 62b
- Epidermal growth factor (EGF), 27
- and oral and pharyngeal cancers, 46
- Epidermolysis bullosa-recessive dystrophic type, 49
- Epithelial cells, cancers of. *See* Squamous cell carcinomas, oral
- Epithelium, 25–26
- aging and, 32
 - nutrition and, 250b
- EPSDT. *See* Early and Periodic Screening, Diagnostic and Treatment Service
- Epstein-Barr virus
- and chemotherapy, 106
 - and oral cancer, 45
 - and oral lesions, 98t
- Erythema multiforme, lesions caused by, 100t
- Erythroplakia lesions, 209
- and squamous cell carcinoma, 44
- Estrogen replacement therapy, and adult periodontitis, 41
- Ethnicity. *See* Race/ethnicity
- Evidence-based practice, 213, 246, 277
- Explorer, visual examination with, for dental caries diagnosis, 198, 200t

F

- Face. *See also* Craniofacial complex
- appearance of, social responses to, 140–141
 - embryonic formation of, 29
 - as reflection of general health, 97–104
- Falls, 50, 72–73. *See also* Injury
- FDA. *See* Food and Drug Administration
- Federal oral health infrastructure, 226–227, 226t
- Federal support
- for dental school programs, 235–236
 - for educational debt, 237
- Fibromyalgia, jaw manifestations of, 52
- Fillings. *See also* Restorations
- materials used in, 201
- Flossing, 39, 176, 190
- and bacteremia, 104
 - and dental caries prevention, 178
 - dental professionals' knowledge of, for dental caries prevention, 178
 - public knowledge of
 - for dental caries prevention, 177
 - and gum disease, 178
 - by tobacco users vs. nonusers, 178
- Fluoride, 155, 158–160
- dental professionals' knowledge about, 177
 - in dentifrices, 159t, 176, 177, 179, 189–190
 - in dietary supplements, 162–165
 - dosage of, 163, 164t
 - effectiveness of, 159t, 163–164
 - public knowledge of, 177
 - in drinking water, 2–3, 18, 159t, 160–162
 - access to, 161, 162f, 162t, 163t
 - costs of, 161
 - effectiveness of, 159t, 160–161

- Fluoride (*continued*)
 history of, 159
 public knowledge of, 177
 recommended concentration levels, 160
 in schools, 159*t*, 162
 enamel hypoplasia from high levels of, 101
 in mouthrinses, 159*t*, 165
 professionally applied, 159–160, 198–199
 public knowledge about, 177
 and rate of dental caries progression, 38–39
 safety of, 160
 in saliva, dental caries protection from, 27, 38, 159
 in varnishes, 159*t*, 165–166
- Folate, and gingivitis, 250*b*
- Folic acid
 birth defects and, 47–48, 172
 cancer and, 251*b*
- Food and Drug Administration (FDA), 225, 226*t*
- Fungal diseases, lesions caused by, 99*t*
- Fusobacterium nucleatum*
 and gingivitis, 39
 and smoking, 41
-
- G**
-
- Gastroenteritis, oral manifestations of, 101
- Gene therapy, 276
- Genes
 and periodontal disease, 203, 203*t*
 and resistance to dental caries, 39
- Genetic derangements. *See also* Developmental disorders
 and clefting abnormalities, 48
 and oral cancer, 46
 and periodontal disease, 41
- Genetics
 and control of embryonic development, 30–31
 and future of oral health, 276, 278–279, 278*f*
 and understanding craniofacial development, 28
- Genomic databases, 279
- Geographical region. *See also* Residence, place of
 and dental care wants, 87*t*
- Germ cell layers, in craniofacial development, 29
- Gingiva
 bleeding and inflammation of, as diagnostic test, 204, 204*t*
 lesions of, diseases and conditions causing, 98*t*–99*t*
 recession of, age and, 31
 surface of, 25
- Gingival crevicular fluid, periodontal infection and, 204*t*, 205
- Gingival erythema, linear, and HIV, 101
- Gingivitis, 39–40
 with adult periodontitis, 40
 and heart disease, 119
 from medication, 107
 and pregnancy, 122
 prevention of, 10, 168–169, 190, 191*t*, 205–206
 by race/ethnicity, 66
- Global ratings, of oral health, 144
- Glossary, 62*b*
- β -glucuronidase, in adult periodontitis, 205
- Glutathione, 47
- Glycemic control, affected by periodontal disease, 114–115, 116*t*–117*t*
- Gonorrhea
 lesions caused by, 99*t*
 pharyngeal, 109
- Growth factors, 27
 and oral cancer, 46–47
 in reducing mucositis, 106
- Guided tissue regeneration, 209
- Guidelines, for clinical practice, 213–214, 215*t*
- Guidelines for School Health Programs to Prevent Tobacco Use and Addiction* (CDC), 170
- Gum disease, prevention of, public knowledge of, 178. *See also* Gingivitis; Periodontal disease
- Gums. *See* Gingiva
-
- H**
-
- Hand, foot, and mouth disease, oral lesions with, 98*t*
- HCFA. *See* Health Care Financing Administration
- Head Start, 226
- Health
 biopsychosocial model of, 134
 broadened meaning of, 2, 17–18
 cultural perspectives on, 134–135
 determinants of, theories and models of, 246–248, 246*f*
 historical trends in
 life expectancy, 275–276
 science and technology, 275
 World Health Organization (WHO) definition of, 133
- Health care
 evidence-based, 213, 246, 277
 expenditures on, 227–228
 Consumer Price Index for, 230*t*, 231*f*
 per capita, 229*f*
 by source of funds, 228*t*
 by type of service, 227*f*, 228*t*, 230*t*
 federal and state programs for, 233–234

- oral care in. *See* Dental care; Oral health care system
- personnel in, collaboration with dental care providers, 225, 227
- trends in, 277
- unmet needs in, 83, 87t
- utilization of, 190–191
- Health Care Financing Administration (HCFA), 225
- Health Field Concept, Lalonde's, 247
- Health maintenance organizations (HMOs), 229, 232, 233t
- Health Plan Employer Data and Information Set (HEDIS), 233
- Health professional schools, future of, 276–277. *See also* Dental schools
- Health Professional Shortage Area (HPSA), 227, 237
- Health Resources and Services Administration (HRSA), 225, 226t
- Healthy People 2000, progress in meeting objectives of, 180t
- Healthy People 2010, 4, 19, 247–248, 248f
- objectives of, by age, 268t
- Heart disease. *See* Cardiovascular disease
- HEDIS. *See* Health Plan Employer Data and Information Set
- Herpangina, oral lesions with, 98t
- Herpes labialis lesions
- location, features, and course of, 98t
- prevalence of, by race/ethnicity, 71
- Herpes simplex virus, 43
- and chemotherapy, 106
- lesions from, by population group, 70
- and oral cancer, 45–46, 209, 210
- oral lesions with, 98t
- as pharyngeal infection, 109
- type 1 (HSV-1), 43
- lesions from, 70, 71f
- and oral cancer, 45
- type 2 (HSV-2), 43
- Herpes zoster, oral lesions with, 98t
- Herpetic gingivostomatitis, primary acute, oral lesions with, 98t
- Herpetic stomatitis, primary, 43
- Herpetiform recurrent aphthous ulcers, 44
- HHANES. *See* Hispanic Health and Nutrition Examination Survey
- Hispanic Health and Nutrition Examination Survey (HHANES), 75
- Hispanics. *See also* Cuban Americans; Mexican Americans; Puerto Ricans
- children of
- insurance coverage of, 278
- oral health of, 75
- dental care among
- nonutilization by, 84t–85t
- utilization by, 80t, 81–82, 81t
- as dental personnel, 236–237, 237t
- oral and pharyngeal cancers and, by sex, 68, 68f
- oral health status of, 75–76
- and ratings of oral health, 144
- toothaches among, 73
- Histoplasmosis, lesions caused by, 99t
- HIV/AIDS Dental Reimbursement program, 238–239
- HIV infection
- human papillomavirus (HPV) and, 43, 71
- and oral candidiasis, 42, 43, 71, 101
- oral lesions with, 98t, 101–102
- oral manifestations of, 97, 101–102
- oral transmission of, 108–109
- and periodontal disease, 41
- and RAU, 44
- and trench mouth, 40
- HMOs. *See* Health maintenance organizations
- Hodgkin's lymphoma, 46
- Home genes, 30
- Homeotic genes, 30
- Hormones, oral fluids in diagnostic tests for, 103, 103t
- Hospice patients, 263, 266, 266t
- Hospitalized patients, and systemic complications due to oral bacteria, 105
- Hospitals, oral health care at, 225
- Hox genes, 30
- HPSA. *See* Health Professional Shortage Area
- HPV. *See* Human papillomavirus
- HRSA. *See* Health Resources and Services Administration
- HSV-1. *See* Herpes simplex virus, type 1
- HSV-2. *See* Herpes simplex virus, type 2
- Human genome, in understanding craniofacial development, 28
- Human Genome Project, 53, 278
- Human immunodeficiency virus. *See* HIV infection
- Human papillomavirus (HPV), 43
- and oral cancer, 43, 45–46, 208t, 209, 210
- prevalence of, 71
- Hypodontia
- in ectodermal dysplasias, 50
- hereditary, 49
- Hypoparathyroidism, oral manifestations of, 101

I

- IFN- γ . *See* Interferon γ
- IgA antibody, 32

- IHS. *See* Indian Health Service
- IL-1. *See* Interleukin 1
- IL-1 β . *See* Interleukin 1 β
- Imaging technologies, 196
 for dental caries diagnosis and treatment, 201
 for oral cancer diagnosis, 210
 for TMD, 212*t*
- Immune cells
 in adult periodontitis, 40–41
 and oral cancer, growth factors and, 46–47
 types of, 28. *See also* B cells; T cells
- Immune system, 27–28
 disorders of, Sjögren's syndrome, 51
 and disruption in oral homeostasis, oral
 candidiasis and, 42
 microbial genome research and, 279
 mucosal, 27–28
 nutrition and, 250*b*
 and RAU, 44
- Immunoglobulins, 28. *See also* IgA antibody
 smoking and, 41
- Immunosuppression
 and bacteremia, 104–105
 oral signs of, 97–100
- Immunosurveillance and control, loss of, and oral
 cancer, 46
- Implants. *See* Dental implants
- Incidence, definition of, 62*b*
- Incidence rate, definition of, 62*b*
- Incisive foramen, embryonic formation of, 29–30
- Income
 and adult periodontitis, 41
 and children
 dental caries and, 63–64, 63*f*, 64*f*
 and insurance coverage, 253
 oral health and, 2, 252
 dental care and
 nonutilization of, 85*t*–86*t*
 utilization of, 80*t*, 81–82, 81*t*
 wants, 87*t*
 and dental caries, 63–64, 63*f*, 64*f*
 and edentulism, 82
 and insurance coverage, 231, 232*f*
 for children, 253
 low-income communities
 dentists in, educational debt and, 237
 expansion of care to, 239
 and oral health, 249
 among Hispanics, 75
 and periodontal disease, 65–66, 66*f*
 and toothaches, 73
- Indemnity plans, 232, 233*t*
- Indian Health Service (IHS), 76–77, 225, 226*t*
 loan repayment program, 237
- Infection, oral. *See also* Mucosal infections;
 Periodontal disease
 bacteremia and, 104–105
 from cancer therapy, 105–107
 infective endocarditis and, 107–108
 protection against. *See also* Immune system
 by mucosal immune system, 27–28
 by saliva, 26–27
 respiratory disease and, 108
- Inflammation, gingival. *See* Gingivitis
- Injury, oral-facial, 50–51. *See also* Falls; Trauma
 in adolescents, 258
 in children, 2, 72, 258*t*
 prevalence of, 72–73
 prevention and control of, 191*t*
 community-based, 173–176, 174*t*–175*t*
 future of, 276
 helmet use, 173, 174*t*–175*t*, 176*b*
 from sports, 50, 73, 173–176, 174*t*–175*t*, 176*b*,
 258
 in young adults, 258
- Insurance
 changing market in, 231–233
 coverage, 12–13, 229–231
 by age, 231
 for children, 2, 253–255, 277–278
 and dental care nonutilization, 86*t*
 and dental care utilization, 80*t*, 81–82, 81*t*,
 229
 among children, 253
 and dental care wants, 87*t*
 by education level, 231, 232*f*
 for elderly, 265
 employer-provided, 229–231, 261–262
 children and, 253
 future goals in, 286
 by income, 231, 232*f*
 by sex and race/ethnicity, 230–231, 232*f*
- Medicaid, 87*t*, 229, 233
 for children, 2, 253–255, 268
 for elderly, 265
- Medicare, 234, 234*t*, 265
 performance measures in, 232–233
 as source of expenditures on dental services,
 228*t*, 231*f*, 231*t*
- State Children's Health Insurance Program,
 (SCHIP) 2, 13, 233–234, 255, 277
 and utilization, 81*t*, 82
- Interferon γ (IFN- γ), and adult periodontitis, 41
- Interleukin 1 (IL-1)
 and adult periodontitis, 41, 205
 and periodontal disease, 203

- Interleukin 1 β (IL-1 β)
 and adult periodontitis, 41
 and periodontal disease, 203
 Interleukin 6, and adult periodontitis, 205
 Interleukins, and heart disease, 115
 Irrigation, to control gingival inflammation, 206t,
 207

J

- Jaw (mandible and maxilla). *See also* Alveolar bone;
 Oral bone
 aging and, 31–32
 bone loss in, osteoporosis and, 102–103

K

- Kaposi's sarcoma, 46, 101
 Keratin, 25
 Keratin genes, mutations in, and epidermolysis
 bullosa, 49
 Keratinocytes, and oral cancer, 46
 Killer cells, and oral cancer, 46

L

- Lacrimal glands, Sjögren's syndrome and, 51
 Lalonde Report, 246–247
 Langerhans cells, and immunosurveillance, 46
 Language
 mechanisms of, 25
 skills, of oral and pharyngeal cancer patients,
 136
 Laser technologies, in dental caries diagnosis and
 treatment, 201
 Leukoplakias, 44, 209
 Lichen planus, lesions caused by, 100t
 Life expectancy, 275–276
 Lifestyle
 of adolescents/young adults, 257–258
 as determinant of health, 190, 191t, 246f,
 247–248
 Lip cancer
 incidence of, 69, 70
 risk factors, 208t, 209t, 210
 sun exposure, 169
 Lips, lesions on, diseases and conditions causing,
 98t, 100t
 LJP. *See* Localized juvenile periodontitis
 Local public health departments, 226, 286
 Localized juvenile periodontitis (LJP), 42
 Lymphocytes, and immunosurveillance, 46.
See also B cells; T cells

M

- Macrophages, cytotoxic, and immunosurveillance,
 46
 Magnetic resonance imaging (MRI), 196
 Malocclusions
 prevalence of, 72
 quality of life with, 141–142
 risk and protective factors for, 258t
 Mandibulofacial dysostosis, 48
 Marijuana, oral cancer and, 45, 208t, 209t
 Masseter muscle, 26
 Mastication, muscles of, 26
 Mechanoreceptors, 24
 Medicaid, 229, 233
 for children, 2, 253–255, 268
 dental vs. other health expenditures for,
 254
 and dental care wants, 87t
 for elderly, 265
 Medical care, in oral health care system, 225
 Medicare, 234, 234t, 265
 and dental care wants, 87t
 Medications
 and dental caries, 38
 and disruption in oral homeostasis, oral
 candidiasis and, 42
 and elderly oral health, 265–266
 and gingivitis, 39
 oral complications of, 107
 Men
 and adult periodontitis, susceptibility to, 41, 65,
 65f
 cancer in
 oral and pharyngeal, by race/ethnicity and
 sex, 68, 68f
 types of, by race/ethnicity, 68, 68f
 and dental care nonutilization, 84t
 and injuries, 73
 and pain, 25
 prevalence of, 73, 73f
 and periodontal disease, 203t
 Metabolites, in detection of periodontal disease, 205
 Mexican Americans
 children
 insurance coverage of, 253
 oral health of, 75
 dental care utilization by, 80t, 81–82, 81t
 and dental caries, susceptibility to, 63–64, 63f,
 64f
 tooth loss by, by economic status, 67, 67f
 Microbes
 genome research on, 279
 oral transmission of, 108–109

Index

- Microbes (*continued*)
 protection against. *See also* Immune system
 by saliva, 26–27
- Micronutrients. *See also* Nutrition
 and cancer prevention, 47
 fluoride as, 160
- Military personnel, dental care among, vs. civilian
 population, 83, 87, 88*f*
- Mononucleosis, infectious, oral lesions with, 98*t*
- Mortality rate, definition of, 62*b*
- Motor vehicle collisions, 50, 73, 173
- Mouth. *See also* Craniofacial complex; Oral cavity
 elements of, 1, 17, 25
 embryonic formation of, 29
 as gateway, 37
 for infection, 104–109
 lesions in, diseases and conditions causing,
 98*t*–100*t*
 as reflection of general health, 1–2, 10–11, 17,
 97–104, 284
- Mouthguard use, 173–175, 174*t*–175*t*, 176*b*
- Mouthrinses, fluoride, 159*t*, 165
- MRI. *See* Magnetic resonance imaging
- Mucins, 27
 aging and, 32
- Mucosal immune system, 27–28
- Mucosal infections, 42–44, 70–71, 212
 by race/ethnicity, socioeconomic status, and sex,
 70–71
- Mucous membrane pemphigoid, lesions caused by,
 100*t*
- Multiple sclerosis, and tic douloureux, 52
- Mumps, swollen parotid glands with, 97
- Mutans streptococci, 37, 38
 median age of acquisition of, 39
 mother as source of, 199–200
 as primary predictor of dental caries incidence,
 196–197, 198*t*
- Mutations
 and craniofacial syndromes, 31, 278–279
 in keratin genes, and epidermolysis bullosa, 49
 and oral cancer, 46
 and periodontal disease, 41
-
- N**
- Nasopharyngeal carcinoma, 45, 76
- National Facial Protection Month, 173
- National Health and Nutrition Examination Survey
 (NHANES), 61, 62
- National Health Interview Survey (NHIS), 61
- National Health Service Corps (NHSC), 237
- National Institute for Dental and Craniofacial
 Research (NIDCR), 213
- National Institutes of Health (NIH), 225, 226*t*
- National Oral Cancer Strategic Planning
 Conference, 169–170
- National Oral Health Plan, 21, 284–286
 components of, 11–13, 284–286
- National Preventive Dentistry Demonstration
 Program, 167
- Necrotizing ulcerative gingivitis, acute, lesions
 caused by, 99*t*
- Necrotizing ulcerative periodontitis, and HIV, 101
- Nervous system, and immune system, 28
- Neural crest, 29
 defective development of, Treacher Collins
 syndrome and, 48
- Neural tube, 29
- Neutrophils
 in adult periodontitis, 40–41
 smoking and, 41
 in early-onset periodontitis, 42
- NHANES. *See* National Health and Nutrition
 Examination Survey
- NHIS. *See* National Health Interview Survey
- NHSC. *See* National Health Service Corps
- Nicotine, endocrine effects of, and oral and
 pharyngeal cancers, 46–47. *See* Tobacco
- NIH. *See* National Institutes of Health
- NIDCR. *See* National Institute of Dental and
 Craniofacial Research
- 4-nitroquinoline-N-oxide, 45
- Nitrosamines, 46
- N-nitrosornicotine, 45
- Nociceptors, 24
- Non-Hodgkin's lymphoma, 46
 misdiagnosis of, 101
 Sjögren's syndrome and, 51
- Nonneuronal tissues, 29
- Nose. *See also* Olfactory system
 embryonic formation of, 29
- Notochord, 29
- Nursing homes, in oral health care system, 225
- Nutrition, 191*t*, 250*b*. *See also* Diet
 and birth defects, 47–48, 172, 211
 and cancer prevention, 47, 169, 251*b*
 and dental caries, 250*b*
 micronutrients in
 cancer prevention properties, 47
 fluoride as, 160
 and oral cancer prevention, 209*t*, 210, 251*b*
 oral tissue as reflection of, 100–101
 and periodontal disease, 250*b*–251*b*
 prenatal and perinatal, 198
 and quality of life, 135–136, 136*t*
 and RAU, 44

O

- Olfactory system, 24
aging and, 32
- Oncogenes
discovery of, 45
and oral and pharyngeal cancer, 46
- Oral, definition of, 1, 17
- Oral bone, loss of, osteoporosis, 102–103
- Oral cavity. *See also* Mouth
elements of, 25–28
manifestations of systemic disease in, 37,
97–101, 98t–100t
- Oral flora, 37
and brain abscesses, 105
- Oral fluids, diagnostic value of, 103–104, 103t, 279,
280t
- Oral health
barriers to, removal of, 4, 12–13, 19, 286
broad definition of, 2, 17–18, 133–134
costs of, 4, 19, 227–228, 227f, 228t, 229f, 230t
indirect, 142–144, 143t
determinants of, 248–249
income inequality, 249
lifestyle, 190, 191t, 246f, 247–248, 283
workplace effects, 249
disparities in, 1, 4, 10, 17, 19, 88, 239, 284
enhancement of, 267–268
for adolescents and young adults, 257–258
for adults, 258–262
for children, 249–257
insurance and, 253–255
social and professional environment
and, 255–257
for elderly adults, 262–267, 263t–264t
for elderly women, 266–267
expenditures for, 227–228, 227f, 228t
financing for, 228t, 229–234, 231f, 231t,
232f
vs. total health care expenditures, 227,
227f, 228t
future of, 280
diversity of diseases and patients in, 276
National Oral Health Plan, 284–286
new treatments in, 276
and general health, 2, 4–5, 10–11, 17–18, 19,
53, 285–286
in elderly, 265
implications of linkages between, 122
risk factors in, 4, 10, 18
historical trends and, 275–276
meaning of, 5, 17–21, 20
of military personnel, vs. civilian population,
83, 87, 88f
objectives for, 267–268, 267t
personal approaches to, 189–191
care seeking, 190–191
daily hygiene, 189–190
among elderly, 262–263
healthy lifestyle, 190, 191t
prevention measures, 3–4, 7–9, 10, 18. *See also*
Oral health care system
in public health programs, 12
ratings of, 144
status of, 35–93
and dental care wants, 87t
trends in, 87–89
- Oral health care system. *See also* Dental care
active personnel in, 223–224, 224t, 235–236,
235f, 286
by sex and race/ethnicity, 11, 236–237,
237t, 286
community approaches in
for craniofacial birth defects, 172–173
for dental caries, 158–168
effectiveness of interventions by, 155–158,
156t
glossary of terms for, 157b
for injury, 173–176
for oral and pharyngeal cancers, 169–172
for periodontal diseases, 168–169
expanding base of, 216
future of, 239–240
capacity to meet needs in, 234–239
molecular, and genomics, 278, 278f, 279
individual approaches in
care seeking in, 190–191
daily hygiene in, 189–190
among elderly, 262–263
healthy lifestyles in, 190, 191t, 246f,
247–249, 248f
knowledge of and practice in, 176–179
professional components of
dental care, 223–224
medical care, 225
overlap among, 227
public health programs, 225–227
progress in, 179–180, 180t
provider-based care in, 191–212. *See also*
Provider-based care
diagnostic tests in, 193, 193t
future of, 212–216
oral health assessment in, 193–196,
194f–195f, 197t
risk assessment in, 192–193
public-private partnerships in, 13, 286
strategies for, 156t
underserved in, 239

- Oral hygiene, 189–190, 191*t*
 and bacteremia, 104
 and dental caries, 39, 189–190
 among elderly, 262–263
 and gingivitis, 39
 and periodontal disease, 168–169, 190, 191*t*, 203*t*
 public practices survey, 178
 workplace effects on, 249
- Oral mucosa, 25–26
 aging and, 32
 lesions of, diseases and conditions causing, 98*t*–100*t*
 nutrition and, 250*b*
 staining of, 107
- ORN. *See* Osteoradionecrosis
- Osteogenesis imperfecta, 49
- Osteoporosis
 and adult periodontitis, susceptibility to, 41
 and oral bone loss, 102–103
 and periodontal disease, 203*t*
- Osteoradionecrosis (ORN), 106
- Ottawa Charter for Health Promotion, 247
-
- P**
- Pain
 facial, atypical, 52
 oral, chronic, 24
 oral-facial, 24–25, 52
 clinical management of, 211
 control of, 24
 impact of, 139–140
 prevalence of, 73, 73*f*
 sex differences, 25, 77
 sleep problems with, 137
- Palate, 25
 embryonic formation of, 29
 lesions of, diseases and conditions causing, 98*t*–100*t*
- Papillae, as oral mucosa, 25
- Papillomavirus, oral lesions with, 71, 98*t*
- Papillon-Lefevre syndrome, and periodontal disease, 41
- Parotid glands, 26
 aging and, 32
 swollen, 97
- Pathogens, protection against. *See also* Immune system
 by saliva, 27
- Pathology, systemic, craniofacial disease as model of, 53
- Pemphigus vulgaris, lesions caused by, 100*t*
- Periodontal attachment
 loss of
 by age, sex, race/ethnicity, and income, 65–66
 definition of, 62*b*
 osteoporosis and, 102
- Periodontal disease, 39–42
 adult periodontitis. *See* Adult periodontitis
 by age, sex, race/ethnicity, and income, 65–66
 from bone marrow radiation, 105
 and cardiovascular disease, 115–120
 clinical management of, 201–209
 diagnosis of, 203–205, 204*t*, 278
 prevention of, 205–206, 206*t*
 risk assessment in, 202–203, 203*t*
 treatment of, 206–209, 206*t*
- diabetes and, 2, 17, 109–114
 glycemic control affected by, 114–115, 116*t*–117*t*
 research used in, 110*t*, 111*t*–113*t*
- early-onset. *See* Early-onset periodontitis
- heart disease and stroke with, 115–120
 animal studies, 117–118
 mechanisms of action in, 115–117
 population-based studies, 118–120, 119*t*
 nutrition and, 250*b*–251*b*
- pathogenesis of, 202
- preexisting, as risk factor, 202, 203*t*
- and pregnancy, adverse outcomes in, 120–122
- prevention of, 10, 168–169, 256*t*
 daily oral hygiene and, 168–169, 190, 191*t*, 203*t*
 dental professionals' knowledge about, 178
 history of, 3, 18
 provider-based, 205–206, 206*t*
 public's knowledge about, 178
 strategies for, 156*t*
 risk and protective factors for, 256*t*
 tobacco and, 259*b*, 260*b*
- Periodontal ligament
 regeneration procedures for, 208
 sensitivity of, 24
 teeth in, 26
 tissue turnover in, 31
- Periodontitis
 adult. *See* Adult periodontitis
 and heart disease, 118–120
 as mixed infection, 205
 necrotizing ulcerative, and HIV, 101
 pathobiology of, 202, 202*f*
 and stroke, 119–120
- Perioral skin, lesions of, diseases and conditions causing, 98*t*
- Pfeiffer's disease, 49
- PGE₂. *See* Prostaglandin E₂

- pH
 in dental caries risk assessment, 197
 saliva and, 27
- Phagocytes, in adult periodontitis, smoking and, 41
- Pharmaceuticals. *See* Medications
- Pharyngeal cancer. *See* Cancer, oral and pharyngeal
- Pharynx, 25
 herpes simplex virus and, 109
 lesions of, diseases and conditions causing, 98t, 100t
- Phenytoin, and gingivitis, 39, 107
- Phosphate metabolism, disturbances in, oral manifestations of, 101
- Pierre Robin syndrome, 48
- Pigmentation, of soft or hard oral tissue, as sign of disease, 100
- Pipe smoking, and cancer, 208t, 259b
- Plaque, 37, 104. *See also* Biofilm
 control of, 39, 205–206, 206t
 chemical, 205
 with daily hygiene, 190
 professional, 206
 fluoride in, 159
 public knowledge about, 178
 subgingival, 40
- Pocket depths, and periodontal disease diagnosis, 204, 204t
- Point mutations, birth defects and, 31
- Polymeric resin composites, in dental caries treatment, 201
- Population, trends in, 275–276, 280
- Population groups
 characteristics of, as determinant of health, 248, 248f
 data on, 10, 61–62, 88
 disabled, oral health of, 78–79
 diversity of, future of oral care and, 277
 oral health disparities among, 1, 4, 10, 17, 19, 88, 239, 283–284
 oral health services targeted to, 225, 239
 racial/ethnic minorities. *See* Race/ethnicity;
specific minority group
 women. *See* Women
- Porphyromonas gingivalis*
 in adult periodontitis, 40, 41, 205
 in adverse pregnancy outcomes, 121
 and bacteremia, 104
 in heart disease, 117
 in periodontal disease, 203t
- Poverty, 249. *See also* Income
 children in, oral health of, 2, 252
 and dental care utilization, 80, 80t, 81
 and dental caries, susceptibility to, 63–64
 and tooth loss and edentulism, 66, 67f
 and toothaches, 73
- PPOs. *See* Preferred provider organizations
- Precancerous lesions
 HPV and, 45
 and oral cancer, 44–45
 and smokeless (spit) tobacco, 70, 70f
- Precavitated carious lesions, in restored teeth, diagnosis of, 198
- Preferred provider organizations (PPOs), 229, 232, 233t
- Pregnancy
 adverse outcomes of, periodontal disease and, 120–122
 and dietary fluoride supplements, 163–164
 gingivitis in, 39
- Prenatal care, 172, 198, 210–211
- Prenatal syphilis, lesions caused by, 99t
- Prepubertal periodontitis, 42
- Prevalence, definition of, 62b
- Prevalence rate, definition of, 62b
- Prevotella intermedia*
 in adult periodontitis, 40, 41
 in periodontal disease, 203t
 in prepubertal periodontitis, 42
 smoking and, 41
- Private practice, 223–224, 227
- Probes/instrumentation, sensitivity of, 40
- Probing depths, and periodontal disease diagnosis, 204, 204t
- Prostaglandin(s)
 and adult periodontitis, 40–41
 and heart disease, 115
 and pregnancy, 121
- Prostaglandin E₂
 and adult periodontitis, 40–41, 205
 and mucositis, 106
 and periodontal disease, and low birth weight, 121
- Proto-oncogenes
 discovery of, 45
 and oral cancer, 46
- Provider-based care, 191–212
 changing approach by
 to birth defects, 210–211
 to dental caries, 196–201
 to oral and pharyngeal cancers, 209–210
 to periodontal diseases, 201–209
 for chronic craniofacial pain and sensorimotor conditions, 211
 diagnostic tests in, 193, 193t
 dental caries, 198, 200t
 oral and pharyngeal cancer, 210
 periodontal diseases, 203–205, 204t
 future of

Provider-based care (*continued*)
 broadening base in, 216
 clinical practice guidelines, 213–214, 215t
 evidence-based practice, 213
 science and technology contributions, 216
 for mucosal and autoimmune diseases, 212
 oral health assessment by, 193–196, 194f–195f, 197t
 prevention by
 of birth defects, 210–211
 of dental caries, 198–200
 of oral and pharyngeal cancer, 210
 of periodontal diseases, 205–206, 206t
 risk assessment by, 192–193
 of dental caries, 197, 198t, 200t
 of oral and pharyngeal cancer, 208t, 209–210, 209t
 of periodontal diseases, 202–203, 203t
 for temporomandibular disorders, 211–212
 Pseudomembranous candidiasis, 43
 Pterygoid muscle, 26
 Puberty gingivitis, 39
 Public
 knowledge, attitudes, and practices of, 177–179, 239, 280
 perceptions of, 11, 285
 Public health programs. *See also* Community health programs; Medicaid; Medicare
 for elderly, 265
 essential services for, 181b
 in oral health care system, 12, 225–227, 286
 Public-private partnerships, 13, 286
 Puerto Ricans, oral health of, 75
 Pulmonary disease, obstructive, and oral health, 108
 Pulp tissue
 infections in, 24, 38
 tissue turnover in, 31

Q

Quality of life
 cultural perspectives on, 134–135
 heightened expectations of, 146
 oral health in, 133–134
 functional dimensions of
 eating problems and, 135–136, 136t
 sleep problems and, 137
 indirect costs of, 142–144, 143t
 need for measurement of, 133–134
 psychosocial dimensions of, 137–142
 cleft lip/palate and malocclusion, 141–142
 facial appearance, 140–141
 oral and pharyngeal cancers, 142

oral-facial pain and, 139–140
 social function and, 138–139, 139t
 research on, 144–146, 146t

R

Race/ethnicity. *See also* specific minority group
 and adult periodontitis, 41
 and congenital malformations, 72, 72f
 and dental care
 nonutilization, 84t–85t
 utilization, 80t, 81–82, 81t
 wants, 87t
 and dental caries, susceptibility to, 63–64, 63f, 64f
 future of oral care and, 277
 and insurance coverage, 230–231, 232f
 and malocclusions, 72
 in oral health workforce, 12, 236–237, 237t, 286
 and periodontal disease, 41, 65–66, 66f
 Radiation treatment
 oral candidiasis and, 42
 oral infections from, 106
 oral ulcers and oral mucositis from, 26
 periodontal disease from, 105
 Radiographs, 196
 bite-wing, 198, 200t
 in periodontal disease diagnosis, 204, 204t
 Rapidly progressive periodontitis, 40, 41
 systemic antibiotics for, 207
 Ratings, of oral health, 144
 RAU. *See* Recurrent aphthous ulcers
 Recurrent aphthous ulcers (RAU), 43–44
 prevalence of, 71, 71f
 Refractory adult periodontitis, 42
 systemic antibiotics for, 207
 Reimbursement, direct, 230. *See also* Dental care, financing and reimbursement
 Relative survival rate, definition of, 62b
 Remineralization, 27, 38, 159, 199
 Research. *See also* Science base
 current, 4, 5, 11, 19, 20
 in evidence-based practice, 213, 246
 federal studies of oral health, 268
 need for expansion of, 285–286
 on quality of life, 144–146, 146t
 surveys used for health data, 61–62
 trends in, 214–216
 Respiratory disease, oral infections and, 108
 Restorations
 precavitated carious lesions in, diagnosis of, 198
 procedures for, 201
 Retinoids, 47

Rous sarcoma virus (RSV), and oral cancer, 45
 RSV. *See* Rous sarcoma virus
 Rural/urban status, and dental care wants, 87t
 Ryan White Comprehensive AIDS Resources
 Emergency Act, 225

S

- S-IgA, 28
 Saethre-Chotzen syndrome, 49
 Saliva, 26
 aging and, 32
 and cariogenic bacteria, 38
 decreased flow of
 in dental caries risk assessment, 197
 and chewing function, 136
 diagnostic value of, 103–104, 103t, 279, 280t
 fluoride and, 27, 38, 159
 functions of
 barrier and buffering properties, 27
 dental caries prevention, 27
 tissue protection, 26–27
 wound healing, 27
 and general health, 1, 17
 immunoglobulins in, smoking and, 41
 Salivary glands, 26
 and aging, 32
 and general health, 1, 17
 involvement in infections, 97
 Sjögren's syndrome and, 51
 Satisfaction ratings, of oral health, 144
 Scaling and root planing, for plaque removal, 206,
 206t
 SCHIP. *See* State Children's Health Insurance
 Program
 School-based programs. *See also* Dental schools;
 Health professional schools
 dental sealant programs in, 167
 dietary fluoride supplements in, 164–165
 fluoridated drinking water in, 159t, 162
 fluoride mouthrinses in, 165
 oral and pharyngeal cancer prevention
 programs in, 170
 strategies employed by, 156t
 tobacco prevention programs in, 170
 Science base. *See also* Research
 and evidence-based practice, 213, 246
 need for expansion of, 11–12, 285–286
 in oral health, 5, 19–20
 Scientific worldviews, 134–135
 Scurvy, oral signs of, 101
 Sealants. *See* Dental sealants
 Secretory leukocyte protease inhibitor (SLPI), 27
 Self-care. *See* Oral health care system, individual
 approaches in
 Senses, 23–25, 32
 Sex
 and adult periodontitis, susceptibility to, 41, 65,
 65f
 and dental care
 nonutilization, 84t
 utilization, 80t, 81–82, 81t
 wants, 87t
 of dental personnel, 236–237
 and injuries, 73
 and insurance coverage, 231, 232f
 and oral and pharyngeal cancers, by race/eth-
 nicity, 68, 68f
 and oral clefts, 72
 and oral health, 77–78
 ratings of, 144
 and pain, 25, 77
 prevalence of, 73, 73f
 and periodontal disease, 203t
 and Sjögren's syndrome, prevalence of, 73
 and taste, 78
 and TMDs, prevalence of, 73
 and tooth loss, 66
 Sex hormones
 and adult periodontitis, susceptibility to, 41
 pain and, 25
 Sexually transmitted diseases (STDs), oral transmis-
 sion of, 109
 Single-gene defects, 49–50
 Sjögren's syndrome, 51
 prevalence of, 73
 swollen parotid glands with, 97
 Skin, lesions of, diseases and conditions causing,
 98t, 100t
 Sleep problems, and quality of life, 137
 SLPI. *See* Secretory leukocyte protease inhibitor
 Smell
 aging and, 32
 development and function of, 23, 24
 Smokeless (spit) tobacco. *See* Tobacco
 Smoking. *See also* Tobacco
 and birth defects, 48
 cessation of, 210
 community intervention models, 171
 and oral cancer, 46
 and periodontal disease, 203t, 206
 school-based intervention models, 170
 and trench mouth, 40
 Social function, and dental problems, 138–139, 139t
 Socioeconomic status. *See* Income
 Sonic instruments, for plaque removal, 206, 206t
 Spinal chord, early development of, 29
 Spirochetes, and trench mouth, 40

Index

- Sports injuries, 50, 73, 173–176, 174*t*–175*t*, 176*b*, 258
- Squamous cell carcinomas, oral, 44
 HPV and, 43, 45
- Stannous fluoride, to limit gingival inflammation, 205, 206*t*
- State Children's Health Insurance Program (SCHIP), 2, 13, 233–234, 255, 277
- States
 data from, need for, 10, 88, 284, 285
 on edentulism, 67*t*
 income of, and population-per-dentist ratio, 224, 224*f*
 on mortality rates for oral and pharyngeal cancer, 70, 70*t*
 public health systems in, 226–227, 286
- STDs. *See* Sexually transmitted diseases
- Steroid hormones, and gingivitis, 39
- Stevens-Johnson syndrome, lesions caused by, 100*t*
- Streptococci, 39. *See also* Mutans streptococci
- Streptococcus sanguis*, in heart disease, 107, 117
- Streptococcus viridans*, oral infections from, 105
- Stress
 and immune system, 28
 and periodontal disease, 203*t*, 206
- Stroke, oral infection and, 115–120
 animal studies, 117–118
 mechanisms of action in, 115–117
 population-based studies, 118–120, 119*t*
- Student indebtedness, 237–238
- Sublingual glands, 26
- Submandibular glands, 26
 aging and, 32
- Submucous fibrosis, and oral cancer, 45
- Sugars
 and dental caries, 38, 250*b*
 intake reduction of, 199
 in smokeless (spit) tobacco, 39
- Surveillance data, 61–62
 need for, 12, 88–89
 on quality of life, 144–146, 146*t*
 surveys used for, 61–62
- Survival rate, definition of, 62*b*
- Syphilis, lesions caused by, 99*t*, 109
- T**
-
- T cells, 28
 smoking and, 41
- Tar, tobacco
 carcinogens in, 45
 dysplasia and, 46
- Tartar, and gingivitis, 39. *See also* Calculus
- Task Force on Community Preventive Services, 158, 180
- Taste
 development and function of, 23–24
 sex differences in, 78
- Tear glands, Sjögren's syndrome and, 51
- Technology, future of, 278–279
- Temperature, sensitivity to, 24–25
- Temporalis muscle, 26
- Temporomandibular disorders (TMDs), 52–53
 and chewing function, 136
 clinical management of, 211–212
 diagnosis of, 211–212, 212*t*
 pain from, impact of, 139–140
 prevalence of, 73
 and quality of life, 145–146
 treatment for, 212
- Temporomandibular joint, 26
- Teratogens, 47–48
- Tetracycline, enamel hypoplasia from, 107
- TGF- α . *See* Transforming growth factor α
- Therapeutics, oral fluids in diagnostic tests for, 103, 103*t*
- Thermoreceptors, 24
- Thrombosis, from oral cavity bacteria, 117
- Thromboxane B₂, and heart disease, 115
- Thrush, 43. *See* Candidiasis
 prevalence of, 71
- Tic douloureux, 52
- TMDs. *See* Temporomandibular disorders
- TNF- α . *See* Tumor necrosis factor α
- Tobacco, 191*t*
 among adolescents, 259*b*
 and adult periodontitis, susceptibility to, 41
 and alcohol, combination of
 and oral cancer, 45, 208*t*, 209
 and dental caries, 259*b*
 as general health risk factor, 4, 10, 18
 and oral and pharyngeal cancer, 259*b*, 260*b*
 and oral cancer, 44–45, 169, 170, 208*t*, 209, 209*t*
 and oral candidiasis, 42
 oral effects of, 101
 and oral mucosal lesions, 70
 and periodontal diseases, 169, 259*b*, 260*b*
 and saliva, 27
 smokeless (spit) tobacco
 among adolescents, 257
 and dental caries, 259*b*
 and oral and pharyngeal cancer, 44–45, 208*t*, 259*b*
 and oral mucosal lesions, 70, 70*f*
 and periodontal diseases, 259*b*

- prevention programs for, 170
and tooth decay, 39
trends in use of, 259b–260b
- Tongue
cancer in, 70
lesions of, diseases and conditions causing,
98t–100t
- Tooth/teeth, 26
aging of, 31
birth defects involving, 48–49, 50
clenching of, 190, 191t, 212
conically shaped, in ectodermal dysplasias, 50
cultural significance of, 137–138
decay in. *See* Dental caries
embryonic development of, 30
grinding of, 52, 212
loss of
by age, socioeconomic status, sex, and
race/ethnicity, 66–67
and chewing function, 135–136
malocclusions. *See* Malocclusions
nutrition in development of, 250b
pain in, 24
primary, 26
restored. *See* Restorations
staining of, 107
thermal sensitivity in, 24
trauma to
from falls, 50
prevalence of, 72
- Toothbrushing, 39, 176, 179, 190
and bacteremia, 104
public knowledge of
for dental caries prevention, 177
for gum disease prevention, 178
public practices, 178
- Toothaches, prevalence of, 73, 73f
- Toothpaste. *See* Dentifrice
- Touch, sense of, in mouth, 24
- Toxic-shock-like syndrome (TSLs), 105
- Toxins, saliva and, 27, 103, 103t
- Transforming growth factor α (TGF- α), and oral
and pharyngeal cancers, 46, 47
- Trauma. *See also* Injury, and oral-facial
prevention of, strategies for, 156t
and RAU, 44
- Traumatic ulcers, lesions caused by, 100t
- Treacher Collins syndrome, 48
- Treatment(s). *See also* specific disease
future of, 276
outcomes
as determinant of health, 248, 248f
measurement of, 133
- Trench mouth, 40
lesions with, 99t
- Treponema*, and gingivitis, 39
- Treponema denticola*, in adult periodontitis, 40, 205
- Triclosan copolymer, to limit gingival inflammation,
205, 206t
- Trigeminal ganglion, oral herpes and, 43
- Trigeminal neuralgia, 52
- TSLs. *See* Toxic-shock-like syndrome
- Tuberculosis, lesions caused by, 99t
- Tumor necrosis factor α (TNF- α)
and adult periodontitis, 41, 205
and glycemic control, 114
and heart disease, 115
and pregnancy, 121
- Tumor suppressor genes, mutations of, in oral and
pharyngeal cancer, 46
-
- U
- Ulcerative colitis, and RAU, 44
- Ultrasonic instruments, for plaque removal, 206,
206t
- U.S. Department of Agriculture, 225
- U.S. Department of Defense, 225
- U.S. Department of Health and Human Services
(USDHHS), 225, 226, 226t
- U.S. Department of Justice, 225
- U.S. Department of Transportation, 225
- U.S. Department of Veterans Affairs, 225
- U.S. Preventive Services Task Force, 156–158
- USDHHS. *See* U.S. Department of Health and
Human Services
-
- V
- Van der Woude syndrome, 48
- Varicella-zoster virus
and chemotherapy, 106
oral lesions with, 98t
- Vascular endothelial growth factor (VEGF), 27
- VEGF. *See* Vascular endothelial growth factor
- Veillonella parvula*, and gingivitis, 39
- Velocardiofacial syndrome, 48
- Venereal warts, 71
- VGS. *See* Viridans group streptococci
- Vietnamese Americans, nasopharyngeal cancer inci-
dence and mortality, 76
- Vincent's infection, 40
lesions caused by, 99t
- Violence, 51, 72–73
- Viridans group streptococci (VGS), 105
- Viridans streptococcal shock syndrome (VSSS), 105

Viruses. *See also specific virus*
 chemotherapy and, 106
 lesions caused by, 98t
 oral cancer and, 45–46
 Vitamin B deficiency, oral signs of, 101
 Vitamin C deficiency
 and cancer, 251b
 oral signs of, 101
 Vitamin D deficiency, oral signs of, 101
 Vitamin E, 47
 cancer and, 251b
 and mucositis, 106
 VSSS. *See* Viridans streptococcal shock syndrome

W

Waardenburg syndrome, 50
 Warts, viral, 43
 oral lesions with, 98t
 Water fluoridation. *See* Fluoride, in drinking water
 Well-being
 and oral diseases, 10, 11
 and oral health, 2, 4–5, 18, 19
 in World Health Organization (WHO)
 definition of health, 133
 Western scientific worldviews, 134–135
 WHO. *See* World Health Organization
 WIC. *See* Women, Infants, and Children program
Wolinella recta, in adult periodontitis, 41
 Women
 and adult periodontitis, susceptibility to, 41, 65,
 65f

and dental care nonutilization, 84t
 as dental personnel, 236
 in dentistry, 223–224, 224t
 elderly, risk factors for, 266–267
 and injuries, 73
 and oral and pharyngeal cancers, 68, 68f
 and oral bone loss, 102–103
 oral health of, 77–78, 266–267
 areas of study in, 78, 78f
 and pain, 25, 77–78
 prevalence of, 73, 73f
 TMDs, 52, 73
 and Sjögren's syndrome, prevalence of, 73
 Women, Infants, and Children (WIC) program, 225,
 256
 Workplace effects, on oral health, 249
 World Health Organization (WHO) 18, 133

X

Xenografts, 208
 Xerostomia. *See* Dry mouth
 and dental caries, 38
 and oral candidiasis, 42
 Xerostomic side effects, of medication, 107

Y

Yeast. *See* *Candida albicans*